Significant Ownership of Stonepine Capital Management, LLC
- Signature - Title
- /s/ Jon M. Plexico - Managing Member
- Location
- Bend, OR
- Summary
- This page shows a list of all the recent SCHEDULE 13D/G filings made by Stonepine Capital Management, LLC.
Follow Filing Activity
Follow Stonepine Capital Management, LLC and return when a new Schedule 13D/G filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
CIK context first
Continue from Stonepine Capital Management, LLC
Significant Ownership of Stonepine Capital Management, LLC
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| QNRX | Quoin Pharmaceuticals, Ltd. | Ordinary Shares | 11% | $47,201,973 | +$3,465,711 | 3,271,100 | +7.9% | Stonepine Capital Management, LLC | 29 Jan 2026 |
| CRIS | CURIS INC | Common Stock | 9.9% | $4,468,851 | 4,025,992 | Stonepine Capital Management, LLC | 17 Mar 2026 | ||
| INAB | IN8BIO, Inc. | Common Stock | 9.9% | $1,975,660 | 1,007,990 | Stonepine Capital Management, LLC | 19 Dec 2025 | ||
| AYTU | AYTU BIOPHARMA, INC | Common Stock | 9.9% | $1,975,217 | 906,063 | Stonepine Capital Management, LLC | 30 Jun 2025 | ||
| CNSP | CNS Pharmaceuticals, Inc. | Common Stock | 9.9% | $402,671 | +$279,627 | 159,790 | +227% | Stonepine Capital Management, LLC | 31 Mar 2026 |
| CLRB | Cellectar Biosciences, Inc. | Common Stock | 9.9% | 863,277 | Stonepine Capital Management, LLC | 04 May 2026 | |||
| OPTN | OptiNose, Inc. | Common Stock | 7.8% | $7,176,688 | +$1,819,909 | 788,647 | +34% | Stonepine Capital Management, LLC | 31 Mar 2025 |
| TELA | TELA Bio, Inc. | Common Stock | 6% | $2,211,913 | 2,353,099 | Stonepine Capital Management, LLC | 31 Dec 2024 | ||
| CALC | CalciMedica, Inc. | Common Stock | 4.6% | $949,295 | -$170,674 | 628,672 | -15% | Stonepine Capital Management, LLC | 31 Mar 2025 |
| VSTM | Verastem, Inc. | Common Stock | 4.3% | $23,576,383 | -$1,441,948 | 2,670,032 | -5.8% | Stonepine Capital Management, LLC | 30 Sep 2025 |
| APRE | Aprea Therapeutics, Inc. | Common Stock | 4.3% | $418,978 | -$82,213 | 239,416 | -16% | Stonepine Capital Management, LLC | 31 Mar 2025 |
| INO | Inovio Pharmaceuticals, Inc. | Common Stock | 3.8% | $2,683,444 | -$900,721 | 1,434,997 | -25% | Stonepine Capital Management, LLC | 31 Mar 2025 |
| TENX | Tenax Therapeutics, Inc. | Common Stock | 3.7% | $14,588,992 | 975,200 | Stonepine Capital Management, LLC | 31 Mar 2026 | ||
| SRZN | Surrozen, Inc./DE | Common Stock | 3.6% | $6,531,368 | -$3,973,019 | 316,289 | -38% | Stonepine Capital Management, LLC | 31 Dec 2025 |
| KZR | Kezar Life Sciences, Inc. | Common Stock | 2.1% | $968,310 | -$1,370,578 | 156,179 | -59% | Stonepine Capital Management, LLC | 31 Dec 2025 |
| EDSA | Edesa Biotech, Inc. | Common Stock | 0.3% | $177,000 | -$3,914,951 | 30,000 | -96% | Stonepine Capital Management, LLC | 31 Mar 2026 |
Schedules 13D/G Reported by Stonepine Capital Management, LLC:
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.